Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171498 | 0.86 | EPHX2 (0.35) | CYP2D6EPHX2MLYCDAPLNRCA1 | |
| SCHEMBL9098228 | 0.82 | CA7 (0.41) | CYP2D6EPHX2MLYCDAPLNRCA1 | |
| SCHEMBL22880791 | 0.79 | CYP2D6 (0.36) | CYP2D6EPHX2MLYCDAPLNRCA1 | |
| SCHEMBL3485766 | 0.77 | EPHX2 (0.40) | CYP2D6EPHX2MLYCDAPLNRCA1 | |
| SCHEMBL26030784 | 0.77 | LMNA (0.33) | CA12CA14CA7 | |
| SCHEMBL22881073 | 0.76 | CYP2D6 (0.35) | CYP2D6EPHX2MLYCDAPLNRCA1 | |
| SCHEMBL948270 | 0.76 | EPHX2 (0.37) | CYP2D6EPHX2MLYCDAPLNRCA1 | |
| SCHEMBL23225912 | 0.75 | MAOA (0.41) | CA1CA2CA12CTSKCA7 | |
| SCHEMBL948359 | 0.74 | PAOX (0.38) | CYP2D6EPHX2MLYCDCA1CA2 | |
| SCHEMBL18508164 | 0.73 | MEN1 (0.44) | CYP2D6APLNRCA1CA2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | NOTCH1, NOTCH2, HES1 | CYP2D6 3944/4885EPHX2 2625/4885MLYCD 1072/4885 |
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MKI67, CCNI, KRAS | CYP2D6 1641/4885EPHX2 4028/4885MLYCD 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.